AnoVac

AnoVac is a private U.S. biotechnology company focused on cancer immunotherapy. The company appears to operate as or alongside Icell Kealex Therapeutics and has been described as developing proprietary oncolytic virus-based cancer immunotherapeutics, with additional work in CAR-NK and CAR-T approaches. Publicly available pipeline intelligence indicates a preclinical portfolio centered on solid tumors and hematologic malignancies, with programs involving targets such as CD19, GD2, fibroblast activation protein alpha, and ephrin type-A receptor 2. AnoVac has also been described as a subsidiary of Ansun BioPharma in Houston-area operations. Overall, the company is best characterized as an early-stage immuno-oncology platform company with a focus on engineered viral and cell-based therapies.